Pfizer stays with Rigel:
siliconinvestor.com
>>Rigel Announces Extension of Asthma/Allergy Drug Discovery Collaboration With Pfizer
SOUTH SAN FRANCISCO, Calif., Jan 25, 2001 /PRNewswire via COMTEX/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL chart, msgs) today announced that Pfizer has elected to extend the asthma/allergy research collaboration with Rigel for an additional year. The ongoing research will be conducted at Rigel and Pfizer will provide additional research funding.
"We are delighted that that Pfizer considers the work with Rigel a priority and has chosen to renew the collaboration," said James M. Gower, president and chief executive officer of Rigel. "It is a tremendous validation of our drug discovery technology and we look forward to continued progress."
The companies originally entered into a two-year agreement in January 1999 to use Rigel's proprietary peptide libraries to identify intracellular drug targets that control the production of IgE, a key mediator in allergic reactions and asthma in B cells. Under the terms of the extended agreement, Pfizer will provide research funding to Rigel for an additional year, as well as research milestones. Rigel will also receive royalty payments relating to the development and commercialization of any human or animal therapeutics resulting from the collaboration. In return, Pfizer will have worldwide rights to develop and market human and veterinary drugs against the targets that inhibit the switch to IgE in B cells.
Rigel uses post-genomics combinatorial biology technology to discover novel drug targets. Post-genomics combinatorial biology technology is designed to identify molecules which play an important role in regulating a human cell's response to disease by testing a very large number of proteins in a very large number of cells to determine which proteins will change the cell's response to the disease. Rigel currently has programs in asthma/allergy, autoimmunity, transplant rejection, rheumatoid arthritis, inflammatory bowel disease, cancerous tumor growth and hepatitis C. Rigel has a collaboration with Pfizer Inc. and multi-year collaborations with Cell Genesys, Inc., Janssen Pharmaceutica N.V. and Novartis Pharma A.G. Rigel is based in South San Francisco, California.<<
snip
Cheers, Tuck |
